Related Experiment Video
Updated: Feb 5, 2026

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
Published on: May 30, 2013
Institutional Review Boards as Arbiters of Expanded Access to Unapproved Drugs: Time for a Change?
Barbara K Redman1, Alison Shea Bateman-House1
11 New York University School of Medicine, New York, NY, USA.
Abstract:
Institutional review boards (IRBs) are one of the bodies charged with prospectively reviewing compassionate use, the hopefully therapeutic use of an unapproved drug in a seriously ill or dying patient who has no other treatment options. However, there are ethical issues in assigning this role to a body whose primary purpose is to review research proposals. The role of IRBs with regard to compassionate use must be examined and potentially revised.
Related Concept Videos
Time Course of Drug Effect
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Global Climate Change
Rates of Change

